# A Reading Desk, Not a Clinic or a Store

> About Peptide Messengers — Peptide Messengers is an independent research digest reading five research peptides through one frame: the body's own chemical signaling. How this site is built, and its editorial stance.

**ABOUT**

Why this site exists, how it reads the literature, and what it will not do.

## What this site is

Peptide Messengers is an independent research digest covering five research peptides — semaglutide, ipamorelin, GHK-Cu, PT-141, and MOTS-c — through a single organizing idea: each one is a chemical messenger, a signal the body either already uses or closely borrows the receptor logic of. That frame is a reading lens, not a claim that the five compounds share a risk profile, an approval status, or a level of evidence. They do not, and the site is built to keep those differences visible rather than smoothing them over for a tidier narrative.

We are not a clinic, a pharmacy, or a vendor. Nothing on this site is for sale, and no page recommends a dose for any individual. Where a compound has an FDA-approved indication, we say so and cite the trials behind it. Where it does not, we say that plainly too.

## How we read the literature

Every quantitative claim on this site — a percentage, a hazard ratio, a sample size, a half-life — traces to a specific cited source, numbered and listed on the [references page](/references). We distinguish three tiers of evidence throughout: controlled human trials, animal and cell studies, and anecdotal community reports, and we label anecdotal material explicitly wherever it appears rather than blending it with clinical findings. When a finding is negative, mixed, or contested — a missed trial endpoint, a disputed re-analysis, an unconfirmed cancer signal — we report that as carefully as we report a positive result. A literature digest that only reports favorable findings is not doing the job a reader actually needs from it.

## What we will not do

We will not recommend a human dose for any compound, describe a purchase pathway, or use second-person language telling a reader what to take. We will not present a research-community anecdote as clinical evidence, and we will not omit a safety caution because it is inconvenient to the compound's popularity. Two of these five compounds — semaglutide and PT-141 — have FDA-approved forms for specific indications; the other three do not, and treating research-chemical material as equivalent to an approved pharmaceutical would be a real disservice to a reader trying to understand actual risk.

## Who maintains this

Peptide Messengers is edited and maintained as an independent literature digest. Content is sourced from peer-reviewed journals, clinical-trial registries, regulatory labeling, and, where explicitly labeled, patient- and research-community reporting. See [Contact](/contact) for how to reach the editorial desk.

---

A reading desk for the body's own chemical signaling — not a clinic, not a vendor, and never the source of a dose.